May 21, 2015

1st Circ. Strengthens Preemption For Brand-Name Drug Cos.

A February appellate court decision in Marcus v. Forest Pharmaceuticals upheld the dismissal of putative class action claims against the manufacturers of the anti-depressant drug Lexapro. In an article published in Law 360, FaegreBD attorneys Joe Winebrenner and Nick Teichen explained how the ruling indicates a significant shift in how courts apply “impossibility” preemption clauses to consumer protection suits involving brand-name pharmaceuticals.

“The reasoning of the decision should have a practical impact that extends well-beyond the facts of the case,” Winebrenner and Teichen said. “[The ruling] should bolster preemption arguments in other contexts where FDA involvement is required before manufacturers are authorized to take action.”

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.